Lantern Pharma, a clinical stage biotechnology company focused on leveraging artificial intelligence, machine learning and genomic data to streamline the drug development process and to identify the patients that will benefit from its targeted oncology therapies, has entered into agreements with several contract manufacturing companies for process development and manufacturing for two of Lantern’s oncology drug candidates, LP-300 and LP-184. The company also filed an 8-K on Thursday, July ...